Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

38%

3 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4

2(50.0%)

Phase 3

1(25.0%)

Phase 2

1(25.0%)

4Total

Phase 4(2)

Phase 3(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07433010Recruiting

German Dementia Registry

Role: collaborator

NCT02344472Phase 3Active Not Recruiting

Detect V / CHEVENDO (Chemo vs. Endo)

Role: collaborator

NCT04202159Completed

A Study to Evaluate the Effectiveness of Perampanel as Only Add-on Treatment in Participants With Primary or Secondarily Generalized Tonic-clonic Seizures

Role: lead

NCT03841201Phase 2Completed

Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma

Role: collaborator

NCT05033769Phase 4Unknown

Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer

Role: collaborator

NCT03027245Completed

Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy

Role: lead

NCT03082222Completed

ZEDEBAC: Zebinix Effects in Dependency of Baseline Conditions

Role: lead

NCT00165828Phase 4Terminated

Efficacy and Safety of an add-on Treatment With Zonisamide in Adults With Focal Epileptic Seizures With or Without Secondary Generalization

Role: lead

All 8 trials loaded